Wednesday, November 18, 2026 Evidence-led medical research news
The First Cohort
Medical research, with the receipts

rare-disease

15 stories tagged "rare-disease"

Drugs & FDA

A Sugar Ring for Niemann-Pick Type C Won FDA Approval After Its Only Randomized Trial Failed

The FDA says 36 children on adrabetadex reached a median survival of 8.5 years, against 4.9 in matched outside controls. Its only randomized trial missed, its price is unannounced, and its label warns of permanent hearing loss.

Nutrition & Food

Vitamin B12 Rescued Worms With a Rare Childhood-Disease Mutation, and Patients Run Short of the Molecule It Helps Make

Eight Verheij syndrome patients had about 85 percent less methionine in their blood than controls, the molecule a B12-dependent enzyme regenerates. The vitamin was tested in worms, not in them.

Drugs & FDA

Inovio's Accelerated-Approval Drug Is Headed for a $460,000 List Price, Matching the Rival the FDA Approved Outright

Inovio expects to list Voceryq at about $115,000 a dose, the same as Precigen's fully approved Papzimeos, then raised about $80.5 million in stock while the trial meant to confirm its benefit still lacks a final protocol.

Drugs & FDA

Inovio Gets Its First FDA Approval After 7 of 26 Patients Went a Year Without Surgery

In December, the FDA's preliminary view was that Inovio hadn't justified the accelerated pathway. On Friday it granted it, on an uncontrolled trial whose confirmatory study still has no agreed protocol.

Drugs & FDA

GenSight's Blindness Gene Therapy Reached the NEJM on the Same Day It Reported €0.7 Million in Cash

Seven of ten patients blinded by retinitis pigmentosa sensed more light through special goggles after one gene injection, in an uncontrolled trial whose sponsor held €0.7 million on September 30 and warned it may not survive the year.

Drugs & FDA

One Hormone Starves the Brain and Floods the Heart: The FDA's First MCT8 Drug Treats Only the Flood

Emcitate is being called the first treatment for MCT8 deficiency, but its FDA label covers the racing heart and the wasting body, not the brain disability that defines the disease.

Cancer

A Scientist Chased One Missing Blood Marker for Twenty Years. The Answer Was a Tiny Gene Hiding in Plain Sight.

More than 99.9 percent of people carry a blood marker called AnWj. For most of the few who don't, the absence is acquired, a sign of an underlying blood disorder or cancer rather than something they were born with.

Autoimmune & Inflammation

The 47th Human Blood Group Was Hiding in a Protein Almost Too Small to Find

More than 99.9% of us carry the AnWj antigen without knowing. For the rare few born without it, a routine transfusion can turn dangerous, and until now no genetic test could reliably identify them before the damage was done.

Drugs & FDA

The FDA Approved a $3.95 Million Gene Therapy It Rejected Fourteen Months Ago

In July 2025 the FDA refused to approve this Sanfilippo gene therapy and faulted the factory, not the science. Fourteen months later it is the first treatment for a fatal childhood brain disease, cleared on 17 treated children against a comparison group the maker built, at $3.95 million a dose.

Drugs & FDA

The Data on the First Sanfilippo Gene Therapy Were Ready Last Summer. The FDA Spent the Next Year on the Factory.

The FDA said Ultragenyx's clinical data were robust in July 2025, then rejected its Sanfilippo gene therapy over manufacturing questions. Approval came fourteen months later, for children who lose skills and die on a clock.

Drugs & FDA

A Fatal Brain Disease in Children Finally Has a Drug, and It Lists at $1.14 Million a Year

Ionis's zilganersen is the first therapy ever approved for Alexander disease, and it lists near $1.14 million a year. The same FDA approval handed Ionis a rare pediatric disease voucher, the transferable coupon that has resold for as much as $350 million.

Drugs & FDA

A $2.7 Million Gene Therapy, Approved Because Patients Needed Less Cornstarch

Ultragenyx's Genglycos won accelerated approval on a surrogate: a 31 percent cut in daily cornstarch. But the disease is low blood sugar, and by the company's own numbers the treated group spent slightly more time below 70 mg/dL, while liver enzymes spiked in 71 percent and every patient needed ster

Investigations

One Irish Plant Releases Both of Sanofi's Pompe Enzymes. In June, the FDA Called Its Drugs 'Adulterated.'

One Irish plant runs the final release for both of Sanofi's lifelong Pompe enzymes. It just failed an FDA inspection on that exact step, and now the company says the fix could take months while patients confirm their next shipments.

Drugs & FDA

A $440,000 Drug Proved This Obesity Was Never About Willpower

Brain-tumor surgery can wreck the hypothalamus and leave hunger permanently switched on. Setmelanotide restored the missing signal in a real placebo-controlled trial, then arrived priced near half a million dollars a year.

Drugs & FDA

FDA's New Gene Therapy Shortcut Leans on 'Platform Knowledge.' Six Months Ago, They Revoked Sarepta's After Three Patient Deaths.

FDA's new gene therapy draft guidance invites sponsors to lean on "platform knowledge" to streamline submissions, six months after the agency revoked Sarepta's AAVrh74 platform designation following three patient deaths.